Cargando…

Editorial: Molecular Mechanisms and Treatment of MYCN-Driven Tumors

Detalles Bibliográficos
Autores principales:	Suenaga, Yusuke, Einvik, Christer, Takatori, Atsushi, Zhu, Yuyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668800/ https://www.ncbi.nlm.nih.gov/pubmed/34917517 http://dx.doi.org/10.3389/fonc.2021.803443

Ejemplares similares

NLRR1 Is a Potential Therapeutic Target in Neuroblastoma and MYCN-Driven Malignant Cancers
por: Takatori, Atsushi, et al.
Publicado: (2021)

Molecular Mechanisms of MYCN Dysregulation in Cancers
por: Liu, Ruochen, et al.
Publicado: (2021)

Editorial: Targeting MYCN in Pediatric Cancers
por: Sala, Arturo
Publicado: (2015)

Targeting MYCN in Molecularly Defined Malignant Brain Tumors
por: Borgenvik, Anna, et al.
Publicado: (2021)

Molecular mechanisms of MYCN-dependent apoptosis and the MDM2–p53 pathway: an Achille’s heel to be exploited for the therapy of MYCN-amplified neuroblastoma
por: Petroni, Marialaura, et al.
Publicado: (2012)

ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma
por: Hasan, Md. Kamrul, et al.
Publicado: (2013)

MYCN: from oncoprotein to tumor-associated antigen
por: Pistoia, Vito, et al.
Publicado: (2012)

MYCN and the epigenome
por: He, Stanley, et al.
Publicado: (2013)

Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma
por: Henriksen, Jørn R, et al.
Publicado: (2011)

Control Analysis of Protein-Protein Interaction Network Reveals Potential Regulatory Targets for MYCN
por: Pan, Chunyu, et al.
Publicado: (2021)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

Metastasis in neuroblastoma: the MYCN question
por: Bhavsar, Swapnil Parashram
Publicado: (2023)

NCYM, a Cis-Antisense Gene of MYCN, Encodes a De Novo Evolved Protein That Inhibits GSK3β Resulting in the Stabilization of MYCN in Human Neuroblastomas
por: Suenaga, Yusuke, et al.
Publicado: (2014)

Targeting MYCN in Pediatric and Adult Cancers
por: Liu, Zhihui, et al.
Publicado: (2021)

MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation
por: Beckers, Anneleen, et al.
Publicado: (2014)

MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma
por: Liu, Tao, et al.
Publicado: (2022)

MYCN Drives a Tumor Immunosuppressive Environment Which Impacts Survival in Neuroblastoma
por: Raieli, Salvatore, et al.
Publicado: (2021)

Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma
por: Hald, Øyvind H., et al.
Publicado: (2018)

Editorial: Neuroblastoma: Signal Crosstalk and Future Insight Into Clinical Trials
por: Ando, Kiyohiro, et al.
Publicado: (2022)

The MicroRNA Landscape of MYCN-Amplified Neuroblastoma
por: Misiak, Danny, et al.
Publicado: (2021)

Editorial: Molecular Advances in Diagnosis and Treatment of CNS Tumors
por: Zhang, Zhao-Hui, et al.
Publicado: (2020)

Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma
por: Buechner, J, et al.
Publicado: (2011)

Editorial: Advances in the Molecular Mechanisms in Gastrointestinal Tumorigenesis and Treatment
por: Zhang, Ruowen, et al.
Publicado: (2022)

Ferroptosis vulnerability in MYCN‐driven neuroblastomas
por: Dasgupta, Shayani, et al.
Publicado: (2022)

MYCN-mediated transcriptional repression in neuroblastoma: the other side of the coin
por: Gherardi, Samuele, et al.
Publicado: (2013)

CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
por: Sussman, Robyn T., et al.
Publicado: (2020)

Reciprocal Induction of MDM2 and MYCN in Neural and Neuroendocrine Cancers
por: Tran, Hung N., et al.
Publicado: (2020)

PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc
por: Li, Zhiheng, et al.
Publicado: (2020)

Editorial: Molecular characteristics and personalized treatment for pediatric brain tumors
por: Feng, Weijun, et al.
Publicado: (2022)

A Novel Mechanism of 17-AAG Therapeutic Efficacy on HSP90 Inhibition in MYCN-Amplified Neuroblastoma Cells
por: Hanna, Reine, et al.
Publicado: (2021)

Editorial: Tumor Microenvironment: Molecular Mechanisms and Signaling Pathways Involved in Metastatic Progression
por: Link, Wolfgang, et al.
Publicado: (2021)

Non-Genomic Control of Dynamic MYCN Gene Expression in Liver Cancer
por: Qin, Xian-Yang, et al.
Publicado: (2021)

Biological Role of MYCN in Medulloblastoma: Novel Therapeutic Opportunities and Challenges Ahead
por: Shrestha, Sumana, et al.
Publicado: (2021)

Editorial: Molecular advances in diagnosis and treatment of CNS tumors, volume II
por: Chen, Clark, et al.
Publicado: (2023)

Editorial: Molecular Mechanisms of Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Editorial: Advances in malignant pleural mesothelioma: Diagnosis, treatment, and molecular mechanisms
por: Mastromarino, Maria Giovanna, et al.
Publicado: (2023)

DNA Ligase 4 Contributes to Cell Proliferation against DNA-PK Inhibition in MYCN-Amplified Neuroblastoma IMR32 Cells
por: Ando, Kiyohiro, et al.
Publicado: (2023)

MicroRNA-193b-3p represses neuroblastoma cell growth via downregulation of Cyclin D1, MCL-1 and MYCN
por: Roth, Sarah Andrea, et al.
Publicado: (2018)

The Role of MYCN in Symmetric vs. Asymmetric Cell Division of Human Neuroblastoma Cells
por: Izumi, Hideki, et al.
Publicado: (2020)

Editorial: Epigenetics and molecular genetics of rare tumors
por: Tognon, Mauro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_182rpni1k7rk2js1c08hhj43q6